The CEO of Arbutus (interim) describes the company's work in hepatitis B and highlights recent EASL data
Michael McElhaugh describes data presented at EASL for the RNAi therapeutics imdusiran, explains the rationale for using a small molecule PD-L1 inhibitor against hepatitis B, and more.